Koselugo and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Koselugo (selumetinib sulfate), especially for people who are female, 30-39 old, have been taking the drug for 1 - 6 months also take Zofran, and have Neurofibroma.

The phase IV clinical study analyzes which people have Weakness when taking Koselugo. It is created by eHealthMe based on reports of 430 people who have side effects when taking Koselugo from the FDA, and is updated regularly.

What is Koselugo?

Koselugo has active ingredients of selumetinib sulfate. eHealthMe is studying from 431 Koselugo users. Check the latest studies of Koselugo.

What is Weakness?

Weakness is found to be associated with 3,638 drugs and 6,618 conditions by eHealthMe. Check the latest studies of Weakness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

430 people reported to have side effects when taking Koselugo.
Among them, 13 people (3.02%) have Weakness.

Among these 13 people:

How long have people been on Koselugo when they have Weakness? *

What is the gender of people who have Weakness when taking Koselugo? *

female: 70 %
male: 30 %

What is the age of people who have Weakness when taking Koselugo? *

What are other drugs people take besides Koselugo? *

What are other side effects people have besides Weakness? *

Fatigue (feeling of tiredness): 7 people, 53.85%
Headache (pain in head): 3 people, 23.08%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 15.38%
Rashes (redness): 2 people, 15.38%
Vulvitis (inflammation of the vulva): 1 person, 7.69%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 1 person, 7.69%
Hordeolum (small collection of pus (abscess) on the eyelid): 1 person, 7.69%
Hallucinations (sensations that appear real but are created by your mind): 1 person, 7.69%
Hair Loss: 1 person, 7.69%
Haematoma (collection of blood outside the blood vessels): 1 person, 7.69%

What are the existing conditions these people have? *

Neurofibroma (non-cancerous tumours that grow on nerves throughout the body): 3 people, 23.08%
Brain Neoplasm Malignant (brain cancer tumour): 2 people, 15.38%
Peripheral Nerve Infection: 1 person, 7.69%
Neurofibrosarcoma (cancerous nerve sheath tumour): 1 person, 7.69%
Malignant Glioma (cancerous tumour of brain a cancer tumour of uncertain origin that arises both in soft tissue and bone): 1 person, 7.69%
Cervix Carcinoma (cancer of cervix): 1 person, 7.69%
Autonomic Nervous System Imbalance (autonomic nervous system is of net equal emphasis): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Koselugo and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Koselugo:

Koselugo (431 reports)

Weakness treatments and more:

Weakness (586,877 reports)

Browse all side effects of Koselugo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,638 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,618 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on selumetinib sulfate (the active ingredients of Koselugo) and Koselugo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.